For that, prospective trials with larger patient cohorts recording metastatic patterns and B2M mutation status are required, which shall reveal whether the good survival of B2M-mutant M1 MSI cancer patients under ICB reflects the biology of the tumor cells, or indicates treatment response. The gene discussed is B2M; the disease is neoplasm.